A novel, non-hormonal reversible contraceptive for men appears to be effective in mice, based on the results of a study ...

Johnson & Johnson’s radiopharmaceutical spurred “profound and durable” responses, however four patient deaths in the ...

Analysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’ expectations for the bispecific ...

The FDA is upgrading its safety warnings related to complications from Hologic’s implantable marker for breast cancer ...

Zealand Pharma’s GLP-1/GLP-2 receptor dual agonist may have only managed at best an average 4.3% reduction in weight loss ...

With analysts looking for a meaningful increase in the number of responses for Regeneron's phase 1/2 solid tumor trial, a ...

Almost exactly five months after CRISPR Therapeutics’ former chief medical officer P.K. Morrow announced her impending ...

Guardant Health’s blood test designed to help screen the population for hidden cases of colorectal cancer may have taken a ...